Researchers launched a unique collaboration on Wednesday aimed at getting cancer drugs to the market more quickly in which three companies will cooperate with the U.S. government and non-profit groups to test five experimental breast cancer drugs.
The five-year, $26 million study called Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis, or I-SPY2, will aim to use DNA to match the best drug to each patient and to more quickly toss out approaches that do not work or are too toxic.
"They'll get the latest and greatest in terms of targeted drugs," Dr. Anna Barker, deputy director of the National Cancer Institute, said in an interview.
"I think it's the future. Government couldn't have done it on their own and these companies couldn't have done it on their own."
Unusually, the companies agreed to share information on using genes to predict how well a patient will respond as part of the Biomarkers Consortium, which includes the U.S. Food and Drug Administration and the National Institutes of Health.
"I-SPY 2 will provide a path to personalized medicine," said Dr. Laura Esserman, a breast cancer surgeon at the University of California San Francisco who will help lead the clinical trials. "We intend that every drug will graduate with a companion marker."
The trial will match patients to one of five experimental drugs:
-- ABT-888 or veliparib, being developed by Abbott Laboratories. The pill is a PARP inhibitor, which blocks a cell repair enzyme used by cancer cells.
-- AMG 655 or conatumumab, a targeted drug being developed by Amgen. It boosts a protein called APO/TRAIL that causes cancer cells to self-destruct.
-- Amgen's AMG 386, an angiogenesis inhibitor that stops tumors from growing blood vessels to nourish themselves.
-- CP-751,871 or figitumumab, being developed by Pfizer Inc to target the insulin growth factor receptor or IGFR.
-- Pfizer's HKI-272 or neratinib, another targeted therapy called a Pan ErbB inhibitor that targets several related receptors used by cancer cells.
The group is negotiating with other companies to add their experimental drugs to the mix.
"It'll speed up the whole process," Barker said.
The drug company lobby group PhRMA estimates it can take as long as 15 years and cost more than $1.3 billion dollars to take a new drug from laboratory to pharmacy.
Patients at 20 cancer centers will be tested right after they get tiny samples of tissue taken in biopsies. Before they ever get surgery, they will be treated with one of the drugs to see if this helps prevent tumor spread.
Up to 12 different cancer drugs will be tested. Unusually, the group has FDA approval to drop and add drugs throughout the course of the trial without having to stop it to write a whole new protocol.
'Meetings happened. Action didn’t,' says Medecins Sans Frontieres report.
WHO said that on many levels, the world is better prepared now than ever before for aflu pandemic
Myanmar health officals say an outbreak of H5N1 bird flu in Mandalay
Tokyo Electric said it has been aware since last spring that radiation levels in water running in one of the plant gutters rise when it rains
Safe drinking water is available at about one-third of the level it was before the conflict erupted nearly five years ago, and supplies are cut-off to punish civilians at times
Elephants in Angola, which suffered decades of civil war, have been observed avoiding heavily-mined areas, suggesting their trunks were warning them to stay away.
Favipiravir halved death rate among some to 15 pct, but WHO says more research required on drug
The first medicine containing stem cells to treat a rare condition caused by burns to the eye has approved.
940 parasite samplescollected at 55 malaria treatment centres across Myanmar and its border regions. They found that almost 40 percent of the samples had mutations in their so-called kelch gene, K13 -- a known genetic signal of artemisinin drug resistance.
Yaws is known to be prevalent in 12 countries in areas where people have little access to healthcare, mainly in West and Central Africa, Asia and the Pacific Islands.
In the past few years, Nepal has seen the numbers of endangered species, such as the Royal Bengal tiger or the one-horned rhino, rise.
The investment would represent as little as 0.1 percent of current national health spending of the low and middle-income countries affected by NTD.
Nearly 1,000 abandoned California sea lions have washed ashore this year in what rehabilitation centers say is a growing crisis for the animals.
West Africa cases of Ebola show the first decrease in three weeks.
"Marijuana fools the brain's feeding system."scientist Tamas Horvath said.
The Department of Health (DOH) announced that a Filipina nurse who recently arrived in the country tested positive for the MERS Coronavirus.